ORPHELIA Pharma will be present in Paris on November, 5th and 6th, for the Rare Diseases Meeting Days. This event is organized by the French Foundation for Rare Diseases every other year, and allows to assist during two days to plenary conferences and scientific round tables on current topics, poster presentations and meetings with researchers, meeting with companies and stakeholders of the sector.  

The organizing committee of the Foundation selected ORPHELIA’s poster entitled “Multicentre retrospective study of temozolomide use in paediatric refractory or relapsed neuroblastoma : Results from analysis of data from French centres”, to be presented during the Rare Diseases Meeting Days.

Do not hesitate to contact us in order to meet at this occasion (hugues.bienayme@orphelia-pharma.eu).

22 October 2019

ORPHELIA at the Rare Diseases Meeting Days
22 October 2019

ORPHELIA Pharma will be present in Paris on November, 5th and 6th, for the Rare Diseases Meeting Days. This event is organized by the French Foundation for Rare Diseases every other year, and allows to assist during two days to plenary conferences and scientific round tables on current topics, poster presentations and meetings with researchers, meeting with companies and stakeholders of the sector.   The organizing committee of the Foundation selected ORPHELIA’s poster entitled “Multicentre retrospective study of temozolomide use in paediatric refractory or relapsed neuroblastoma : Results from analysis of data from French centres”, to be presented during the Rare Diseases Meeting Days. Do not hesitate to contact us in order to meet at this occasion (hugues.bienayme@orphelia-pharma.eu).
[ Read more ]
16 October 2019

ORPHELIA at the annual SIOP Congress
16 October 2019

ORPHELIA Pharma will be present in Lyon on October, 23th to 26th, for the annual SIOP Congress (the 51st Congress of the International Society for Paediatric Oncology). This event aims to bring together the oncology community and share latest advances in paediatric oncology. Do not hesitate to contact us in order to meet at this occasion (jeremy.bastid@orphelia-pharma.eu).
[ Read more ]
15 October 2019

Dr. Caroline Lemarchand appointed Chief Pharmaceutical Development Officer
15 October 2019

ORPHELIA announces the appointment of Dr. Caroline Lemarchand as Chief Pharmaceutical Development Officer Paris and Lyon, October 15th 2019 – ORPHELIA Pharma, a French biopharmaceutical company dedicated to the development and marketing of paediatric drugs in the fields of oncology and neurology, announces the appointment of Dr. Caroline Lemarchand as Chief Pharmaceutical Development Officer, effective September 16, 2019. Caroline Lemarchand, PharmD, PhD, will bring to ORPHELIA Pharma her expertise in pharmaceutical development, acquired during a 20-year career in pharma and biotech companies. Caroline was successively working at Onxeo (formerly Bioalliance Pharma) as preclinical and pharmaceutical development Director before joining Stallergenes Greer as pharmaceutical development Director. Caroline Lemarchand contributed to the development, registration and marketing of several drugs (innovative technologies, new chemical entities, biotherapy), especially in the field of oncology, both in Europe and in the United States. She authored numerous peer-reviewed scientific publications and patents. « We are particularly pleased to welcome Caroline at ORPHELIA Pharma » comments Hugues Bienaymé, Founder and General Manager at ORPHELIA Pharma. « Her deep knowledge of pharmaceutical development and impressive track-record will be a significant asset for a company like ORPHELIA Pharma, which focuses on life-threatening paediatric conditions. Caroline will be instrumental in managing our collaborative partnerships to assemble a portfolio of essential drugs for children ».  « I am excited to be joining ORPHELIA Pharma at this important inflection point with already 2 products approved and several collaborative projects running », says Caroline Lemarchand. « The company is in a privileged position to build a portfolio of drugs for the paediatric community, both in neurology and oncology. Since there are many collaborations already in place, I look forward to leading these partnerships and setting up some new projects ». About ORPHELIA Pharma ORPHELIA Pharma is a biopharmaceutical company based in Paris and Lyon that develops and markets drugs for the treatment of rare and serious paediatric diseases. Our mission is to provide patients with essential hospital products in the fields of epilepsy and oncology with formulations adapted to the paediatric population. Our first product, Kigabeq®, obtained its Marketing Authorization in October 2018 and has been launched in Europe. Our second product, Ivozall®, received a positive opinion from the CHMP in September 2019 recommending the issuance of a European marketing authorization. ORPHELIA Pharma also conducts research projects through academic and industrial collaborations. The main investors are initiative OCTALFA and Pierre Fabre Medicament.
[ Read more ]
30 September 2019

CHMP has adopted a positive opinion for Ivozall®
30 September 2019

ORPHELIA Pharma announces that the CHMP has adopted a positive opinion for Ivozall® (clofarabine 1 mg/ml), an essential medicine intended for the treatment of relapsed or refractory Acute Lymphoblastic Leukaemia in children Paris and Lyon, October 1st, 2019 – ORPHELIA Pharma, a French biopharmaceutical company dedicated to the development and marketing of paediatric drugs in the fields of oncology and neurology, announces today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the issuance of a marketing authorization for Ivozall®. Ivozall® is a solution for infusion containing 1 mg/ml clofarabine and supplied in 20 ml-vials. Clofarabine is an essential medicine for the treatment of relapsed or refractory Acute Lymphoblastic Leukaemia (ALL) in children. Ivozall® will be the first generic form of clofarabine to be authorised under the European centralized procedure. « We are particularly pleased with this decision which comes after continuous efforts of our company together with our partners », comments Jeremy Bastid, Chief Development Officer of ORPHELIA Pharma. « This positive opinion is a key milestone in the process of making Ivozall®, our first medicinal product in oncology, available to the paediatric community ». « The CHMP has acknowledged the interest of Ivozall® in improving health of children with ALL. We are eagerly awaiting the marketing authorisation expected for November 2019 », highlights Hugues Bienaymé, General Manager of ORPHELIA Pharma. « We anticipate to make Ivozall® available to the hospital centres treating ALL patients in some countries from February 2020 », added Gilles Alberici, Chairman of ORPHELIA Pharma. « Other countries will be handled by ORPHELIA distributors, to be selected in the course of 2020 ». About Acute Lymphoblastic Leukaemia Acute Lymphoblastic Leukaemia is a cancer associated with the uncontrolled proliferation of lymphoblasts that invade the bone marrow. The disease progresses rapidly and aggressively and requires immediate treatment. ALL is a rare disease, with around 7,000 people diagnosed each year in Europe. The majority of ALL cases occurs in children. Although rare, ALL is the most common type of childhood cancer. Clofarabine is indicated for the treatment of ALL in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. About ORPHELIA Pharma ORPHELIA Pharma is a biopharmaceutical company based in Paris and Lyon that develops and markets drugs for the treatment […]
[ Read more ]